1. Targeting delivery of lipocalin 2-engineered mesenchymal stem cells to colon cancer in order to inhibit liver metastasis in nude mice.
- Author
-
Harati MD, Amiri F, Jaleh F, Mehdipour A, Harati MD, Molaee S, Bahadori M, Shokrgozar MA, Jalili MA, and Roudkenar MH
- Subjects
- Acute-Phase Proteins administration & dosage, Animals, Cell Differentiation genetics, Cell Proliferation genetics, Colonic Neoplasms genetics, Colonic Neoplasms pathology, Gene Transfer Techniques, Humans, Lipocalin-2, Lipocalins administration & dosage, Liver Neoplasms genetics, Liver Neoplasms pathology, Liver Neoplasms secondary, Liver Neoplasms, Experimental genetics, Liver Neoplasms, Experimental pathology, Mesenchymal Stem Cell Transplantation, Mice, Proto-Oncogene Proteins administration & dosage, Acute-Phase Proteins genetics, Colonic Neoplasms therapy, Genetic Therapy, Lipocalins genetics, Liver Neoplasms therapy, Liver Neoplasms, Experimental therapy, Proto-Oncogene Proteins genetics
- Abstract
One of the major obstacles in cancer therapy is the lack of anticancer agent specificity to tumor tissues. The strategy of cell-based therapy is a promising therapeutic option for cancer treatment. The specific tumor-oriented migration of mesenchymal stem cells (MSCs) makes them a useful vehicle to deliver anticancer agents. In this study, we genetically manipulated bone marrow-derived mesenchymal stem cells with their lipocalin 2 (Lcn2) in order to inhibit liver metastasis of colon cancer in nude mice. Lcn2 was successfully overexpressed in transfected MSCs. The PCR results of SRY gene confirmed the presence of MSCs in cancer liver tissue. This study showed that Lcn2-engineered MSCs (MSC-Lcn2) not only inhibited liver metastasis of colon cancer but also downregulated the expression of vascular endothelial growth factor (VEGF) in the liver. Overall, MSCs by innate tropism toward cancer cells can deliver the therapeutic agent, Lcn2, and inhibit cancer metastasis. Hence, it could be a new modality for efficient targeted delivery of anticancer agent to liver metastasis.
- Published
- 2015
- Full Text
- View/download PDF